首页> 外文期刊>Clinical Interventions in Aging >Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease
【24h】

Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease

机译:β2受体激动剂,β受体阻滞剂及其组合对老年男性慢性阻塞性肺疾病患者心功能的影响

获取原文
           

摘要

Purpose: This study was undertaken to determine the association between cardiac function and therapy with beta2-adrenoceptor agonists (β2-agonists), β-blockers, or β-blocker–β2-agonist combination therapy in elderly male patients with chronic obstructive pulmonary disease (COPD). Patients and methods: This was a retrospective cohort study of 220 elderly male COPD patients (mean age 84.1 ± 6.9 years). The patients were divided into four groups on the basis of the use of β-blockers and β2-agonists. N-terminal fragment pro-B-type natriuretic peptide (NT pro-BNP), left ventricular ejection fraction (LVEF), and other relevant parameters were measured and recorded. At follow-up, the primary end point was all-cause mortality. Results: Multiple linear regression analysis revealed no significant associations between NT pro-BNP and the use of β2-agonists (β = 35.502, P = 0.905), β-blockers (β = 3.533, P = 0.989), or combination therapy (β = 298.635, P = 0.325). LVEF was not significantly associated with the use of β2-agonists (β = ?0.360, P = 0.475), β-blockers (β = ?0.411, P = 0.284), or combination therapy (β = ?0.397, P = 0.435). Over the follow-up period, 52 patients died, but there was no significant difference in mortality among the four groups (P = 0.357). Kaplan–Meier analysis showed no significant difference among the study groups (log-rank test, P = 0.362). After further multivariate adjustment, use of β2-agonists (hazard ratio [HR] 0.711, 95% confidence interval [CI] 0.287–1.759; P = 0.460), β-blockers (HR 0.962, 95% CI 0.405–2.285; P = 0.930), or combination therapy (HR 0.638, 95% CI 0.241–1.689; P < 0.366) were likewise not correlated with mortality. Conclusion: There was no association between the use of β2-agonists, β-blockers, or β-blocker–β2-agonist combination therapy with cardiac function and all-cause mortality in elderly male COPD patients, which indicated that they may be used safely in this population.
机译:目的:本研究旨在确定老年男性慢性阻塞性肺疾病患者的β2-肾上腺素受体激动剂(β2-激动剂),β-受体阻滞剂或β-受体阻滞剂-β2-受体激动剂联合治疗与心脏功能之间的关系( COPD)。患者和方法:这是一项对220名老年男性COPD患者(平均年龄84.1±6.9岁)的回顾性队列研究。根据使用β-受体阻滞剂和β2-激动剂将患者分为四组。测量并记录N端片段前B型利钠肽(NT前BNP),左心室射血分数(LVEF)和其他相关参数。在随访中,主要终点是全因死亡率。结果:多元线性回归分析显示,NT pro-BNP与使用β2受体激动剂(β= 35.502,P = 0.905),β受体阻滞剂(β= 3.533,P = 0.989)或联合疗法之间无显着关联。 = 298.635,P = 0.325)。 LVEF与使用β2受体激动剂(β= 0.360,P = 0.475),β受体阻滞剂(β= 0.411,P = 0.284)或联合疗法(β= 0.397,P = 0.435)无关。 。在随访期间,有52例患者死亡,但四组之间的死亡率无显着差异(P = 0.357)。 Kaplan–Meier分析显示各研究组之间无显着差异(对数秩检验,P = 0.362)。经过进一步的多变量调整后,使用β2受体激动剂(危险比[HR] 0.711,95%置信区间[CI] 0.287–1.759; P = 0.460),β-受体阻滞剂(HR 0.962,95%CI 0.405–2.285; P = 0.930)或联合治疗(HR 0.638,95%CI 0.241–1.689; P <0.366)也与死亡率无关。结论:老年男性COPD患者使用β2-激动剂,β-受体阻滞剂或β-受体阻滞剂-β2-激动剂联合治疗与心脏功能与全因死亡率之间没有关联,这表明它们可以安全使用在这个人口中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号